Program
QL2109
A development code.
Its studies are mostly in Multiple Myeloma · Neoplasms, led by Qilu Pharmaceutical.
Furthest: phase 3, since Dec 16, 20243 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 33 open or running | phase 3since Dec 16, 2024 | Apr 14, 2024 | Dec 2027phase 3 · NCT06742138 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 14, 2024First study: phase 1 study in NeoplasmsFirst studyNCT06371534 · 228 planned · China
- Dec 16, 2024Phase 3 study in Multiple MyelomaNCT06742138 · 284 planned
- Feb 3, 2026Phase 1 study in Multiple MyelomaNCT07400744 · 102 planned
Ahead
- Dec 2027Primary completion: phase 3 study in Multiple MyelomaNCT06742138
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07400744Multiple Myeloma | 1 | Not yet recruiting | Sep 2026 | 102 |
| NCT06742138Multiple Myeloma | 3 | Not yet recruiting | Dec 2027 | 284 |
| NCT06371534Neoplasms · China | 1 | Recruiting | Apr 2025 | 228 |
How it is read
Names in the registry
- “QL2109”, 3 entries
Codes read as this program: QL2109.
Conditions, from the studies’ own filings
- Multiple Myeloma, 2 studies
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.